PatientsVille.com Logo

ABDOMINAL DISTENSION and Azithromycin

PatientsVille

ABDOMINAL DISTENSION Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for ABDOMINAL DISTENSION

ABDOMINAL DISTENSION treatment research studies

Azithromycin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Azithromycin Side Effects

Diarrhoea (164)
Nausea (131)
Vomiting (123)
Dyspnoea (120)
Dizziness (97)
Rash (91)
Pain (75)
Headache (68)
Abdominal Pain Upper (68)
Pruritus (66)
Abdominal Pain (64)
Asthenia (63)
Pyrexia (59)
Urticaria (56)
Malaise (55)
Anxiety (52)
Tinnitus (42)
Hypotension (42)
Hypersensitivity (42)
Cough (40)
Electrocardiogram Qt Prolonged (40)
Pulmonary Embolism (40)
Loss Of Consciousness (39)
Renal Failure Acute (39)
Condition Aggravated (39)
Cardiac Arrest (38)
Insomnia (36)
Pneumonia (35)
Erythema (34)
Weight Decreased (34)
Palpitations (33)
Injury (33)
Chills (31)
Pain In Extremity (31)
Fatigue (31)
Oedema Peripheral (31)
Dehydration (30)
Hyperhidrosis (30)
Tachycardia (30)
Stevens-johnson Syndrome (30)
Rhabdomyolysis (28)
Deep Vein Thrombosis (28)
Deafness (28)
Cholecystitis Chronic (26)
Product Quality Issue (26)
Syncope (26)
Heart Rate Irregular (25)
Feeling Abnormal (25)
Chest Pain (25)
Heart Rate Increased (24)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am sorry you are in pain. But did you not just say you have Pneumonia!? I think that life threatening infection is worse than the diarrhea dont you?

A doctor subscribed this medication to me for a flu. On the 3rd day I had soft tissue blisters in my nose and my nose was swollen. Also my glands under my neck/jaw were sore. The 4th day my checks and jaws also swole up. *DONT_KNOW*

A week after finish the course of 5 day treatment. Itchy red rash developing all over my legs, very itchy. Wonder if I need to go back to my doctor.

Dear, Kindly ref my earlier post on 21/9/10. After 35 days of medication against side effects of azithromycin from different doctors, finally at the end of september 20

Definitely seems to cause a very down mood! Why don't they know this?

Diarrhea after eating. Bad headaches.

Elizabeth, I lost my sense of smell and my taste too. That was 3rd of May 2011. It is 8th of August and I still havent got it back yet. Have you got yours back yet?

Extreme sensitivity of joints experienced - especially hip, knee, ankle - which has effectively rendered walking painful and difficult. Suspicion of impact on tendons, sharp pain around shoulder blades on certain habitual movements, pressur

Got into a deep depression in 96 after taking zithromax and again in 2007 after the same medication. It started with major panick attacks and anxiety and just got worse. The first time I did not think the medication caused it but when it happened the

Hello will Azithromycin make you not sleep ever since i have been taking this i have not slept but 6 hours in three days?

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

I took one Aleve at 3:30 PM and by 6:30 PM I had extreme abdominal pain lasting several hours and now the next day I still am uncomfortable. I will never take Aleve again!!

I AM 35 YEARS AND ON AN PERIMONOPAUSE AND JUST STARTED ACTIVELLE A FEW WEEKS AGO .I THEN STARTED HAVING SEVERE ABDOMINAL PAINS LIKE MENSTUAL PAIN AND DON'T KNOW WHETHER TO STOP OR CONTINUE.

<b>After taking this drug I suffered abdominal pain with diarrhea after eating even small amounts, pain developed with the urge to get to a toilet at once. I had a full blood and liver test and a stool test and all was normal.&nbs

<b>Describe Your Ezetrol Experience Here:</b>Sleeplessness severe pain in muscles and joints nausea and abdominal pain headaches and pain behind eyes chronic fatigue and flat mood

More common<span style='padding-top: 5px; padding-right: 0px; padding-bottom: 5px; padding-left: 30px; color: #444444; display: block;'>- Abdominal pain<span style='padding-top: 5px; padding-right: 0px; padd

25 YR OLD TRAPSPATIENT w/abdominal pain x 10 days. Stopped taking 100mg dail Kineret 3 days ago, now w/fever 100/102. Went to ER 5 days ago, w/no sign of inflammation in labs. Still have severe abdominal pain.&nbsp

Bad taste in my mouth, very bloated and abdominal pain and reflux

25 three boys. I have loved it. Only problem is occasional abdominal pains. Tonight after intercourse i started spotting and i am concerned as i have had this devise for several months and have never experienced this. I found out later that many wome

32 days on ezertrol 10mg and have severe abdominal cramping and look 6months pregnant, don't know where to go from here, back to the Doctor!!!

ABDOMINAL DISTENSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Mortality Reduction After Oral Azithromycin: Mortality Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: All-cause Mortality Rate in children aged 1-60 months;   Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy;   Cost-effectiveness of mass Azithromycin administration, per averted childhood death;   All-cause and cause-specific health clinic visits in 1-60 month-old children
2 Recruiting Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Condition: Ureaplasma Infections
Interventions: Drug: Azithromycin;   Drug: Placebo (for Azithromycin)
Outcome Measures: Survival with microbiological eradication of Ureaplasma;   Physiologic defined bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age;   Death or Neurodevelopmental impairment;   Pulmonary impairment;   Death;   Duration of positive pressure support;   Duration of oxygen supplementation;   Air leaks;   Received postnatal steroids;   Received Non-Study antibiotics;   Pharmacokinetics (PK)/Pharmacodynamics (PD) modelling of time course of Azithromycin plasma concentrations
3 Not yet recruiting Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
Conditions: Malaria, Falciparum;   Chloroquine;   Azithromycin;   Immunization
Interventions: Drug: Azithromycin capsules;   Drug: Placebo;   Biological: Immunization with falciparum;   Drug: Atovaquone/Proguanil;   Biological: Challenge with falciparum
Outcome Measures: Volunteers falciparum positive by thick smear;   Duration of pre-patent period by thick smear;   Kinetics of parasitemia by PCR;   Adverse events;   Immune responses
4 Not yet recruiting Mortality Reduction After Oral Azithromycin: Morbidity Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Presence of malaria parasites on thick blood smear in children 1-60 months;   Fraction of isolates of pneumococcus exhibiting macrolide resistance by nasopharyngeal swabs in children 1-60 months;   Fraction of isolates of Staphylococcus aureus exhibiting macrolide resistance by nasal swabs in children 1-60 months;   Fraction of isolates of Streptococcus pyogenes exhibiting macrolide resistance by oropharyngeal swabs in children 1-60 months;   Evidence of E. coli macrolide resistance in stool specimens in children 1-60 months;   Fraction of conjunctival swabs yielding ocular chlamydia in children 1-60 months;   Height over time in children aged 1-60 months;   Presence of malaria gametocytes, and density of malaria parasites and gametocytes, in children 1-60 months;   Rates of malaria parasitemia among children 1-59.9 months.;   Hemoglobin concentration and presence of anemia (hemoglobin <11 g/dL) in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance in individuals 7-12 years;   Nasopharyngeal pneumococcal macrolide resistance in children aged 1-60 months seen in local health clinics for a respiratory complaint;   Rates of acute respiratory illness among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Presence of the trachoma grades "follicular trachoma" (TF) and "intense inflammatory trachoma" (TI), as defined by the WHO simplified grading system, in children 1-60 months;   Trachoma infection and antibody status in children (1-60 months);   Rates of diarrhea among children 1-59.9 months.;   Carriage rates and proportions E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months;   Carriage rates and proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months;   Nasopharyngeal methicillin-resistant Staphylococcus aureus in children 1-60 months;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Nasopharyngeal pneumococcal resistance to penicillin and clindamycin in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance determinants (ermB and mefA), serotype, and multilocus sequence type in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance to penicillin and clindamycin in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance determinants (mefA, ermB, ermTR) in children 1-60 months;   Microbial diversity in the conjunctival, nasopharyngeal, nasal, oropharyngeal, and intestinal microbiomes of children aged 1-60 months;   Serology for exposure to exotic pathogens cross sectional sample of children aged 1-60 months;   Knee-heel length and head circumference over time in children aged 1-60 months;   Commensal and diarrheagenic E. coli carriage in stool of children aged 1-60 months
5 Recruiting Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Suspension Placebo
Outcome Measures: To determine if treatment of pre-school children with a history of wheeze who present to an Emergency department (ED) with an acute wheezing episode with Azithromycin for 5 days will resolve their symptoms more quickly;   Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will cause these children to use less rescue beta2 agonists than those treated with placebo;   Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will allow these children to remain free of subsequent wheezy episodes longer than those treated with placebo.
6 Not yet recruiting Belgian Trial With Azithromycin During Acute COPD Exacerbations
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Azithromycin
Outcome Measures: Time to treatment failure;   Number of treatment failures;   Time to new exacerbation;   Number of new exacerbations;   Rate of exacerbations;   Days of hospitalisation;   Days of intensive care;   Symptom and quality of life scores;   Pre- and post-bronchodilator FEV1;   Total dose of systemic steroids;   Total days of antibiotic use;   Number of home physician contacts;   Average cost of hospitalization
7 Not yet recruiting Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Conditions: Ocular Inflammation;   Infection Associated Blepharitis;   Keratitis;   Conjunctivitis, Bacterial
Interventions: Drug: Azithromycin 1.5%/Loteprednol 0,5% + placebo;   Drug: Azithromycin 1.5% + Loteprednol 0,5% (separately)
Outcome Measures: Clinical cure;   irradication of pathogens
8 Recruiting Azithromycin for Children Hospitalized With Asthma
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Length of Stay;   Readmission rate;   School missed;   Work missed;   Emergency room visits;   Physician office visits;   Recurrence of asthma symptoms;   Steriod courses
9 Recruiting Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea
Conditions: Diarrhea;   Fever;   Vomiting;   Abdominal Pain
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Duration of diarrhea in days;   number of stools/day
10 Recruiting A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Condition: Trachoma
Intervention: Other: Surveillance and treatment with Azithromycin of newcomer and traveler families
Outcome Measures: The proportion of communities with C. trachomatis infection prevalence of 1% or below;   The proportion of communities with clinical trachoma prevalence of 5% or below;   The trajectory of change in prevalence of infection with C. trachomatis and clinical trachoma;   The community prevalence of new infections of C. trachomatis and clinical trachoma identified;   The presence of active trachoma in children;   The presence of trachomatous scarring in women
11 Recruiting Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation
Condition: Disorder Related to Lung Transplantation
Interventions: Drug: Azithromycin;   Drug: Ora-Plus
Outcome Measures: Mean forced expiratory volume at one second (FEV1, %pred);   Length of intubation;   Length of Intensive Care Unit (ICU) stay;   Length of hospital stay;   Partial Pressure of Oxygen in Arterial Blood over fraction of inspired oxygen fraction - ratio (PaO2/FiO2);   Primary graft dysfunction (PGD) prevalence and score;   6-minute walking distance;   Acute rejection (grade A; grade B) prevalence/severity;   Broncho-alveolar lavage neutrophilia and cytokine/protein profile;   Airway colonization;   Plasma C-reactive protein levels;   Mortality;   Ventilator-free days
12 Recruiting Drug Interaction Study of Azithromycin and Theophylline
Conditions: Chronic Obstructive Pulmonary Disease;   Asthma
Interventions: Drug: Theophylline with Azithromycin;   Drug: Theophylline alone
Outcome Measure: steady-state plasma concentration of theophylline
13 Unknown  Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Drug: N-metil glucamine;   Drug: Azithromycin
Outcome Measures: Proportion of clinically cured patients;   Proportion of patients with failure;   Occurrence of mucosal lesions after treatment;   Proportion of patients presenting new lesions;   Proportion of adverse events on each treatment group
14 Recruiting PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Conditions: Pharyngitis;   Tonsillitis
Intervention: Drug: Azithromycin
Outcome Measure: Best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination
15 Recruiting Azithromycin Against pLacebo in Exacerbations of Asthma
Condition: Asthma
Interventions: Drug: Zithromax;   Drug: Placebo
Outcome Measures: Diary card summary symptom score;   Quality of life;   Time to 50% reduction in symptom score;   Pulmonary Function tests
16 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
17 Recruiting Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children
Condition: Sinusitis
Interventions: Drug: placebo;   Drug: Azithromycin
Outcome Measure: frequence of acute sinusitis during 12 mouths of study period
18 Unknown  The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease
Conditions: Cat-scratch Disease;   Bartonella Infections
Interventions: Drug: prednison and Azithromycin;   Drug: prednison, Azithromycin;   Drug: prednison, Azenil
Outcome Measure: Severity score of lymphadenitis using a lymphadenitis Score (LS).
19 Recruiting Prevention of Bacterial Infections in Newborn
Condition: Neonatal Infection
Intervention: Drug: Azithromycin and Placebo
Outcome Measures: the prevalence of nasopharyngeal carriage of the newborn of any of the following bacteria: 1) Group B Streptococci (GBS) , 2) S.pneumoniae and 3) S.aureus;   Vaginal bacterial Group B Streptococci(GBS), S.pneumoniae and S.aureus) carriage at day six post-delivery. Vaginal bacterial (GBS, S.pneumoniae and S.aureus) carriage at day 8-10 post-delivery
20 Unknown  the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
Condition: Acne
Interventions: Drug: Doxycycline;   Drug: Azithromycin
Outcome Measures: change in acne lesions;   global response rates, patient's own assessment, side effects and compliance